Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 16, 2018 01:00 ET | Source: Novartis Pharma AG

Novartis announces changes to the Executive Committee

Felix R. Ehrat, Group General Counsel, will retire on June 1, 2018 Shannon Thyme Klinger appointed to Group General Counsel Robert Weltevreden appointed Head of Novartis Business Services ...
May 16, 2018 01:00 ET | Source: Novartis Pharma AG

Novartis kündigt Veränderungen in der Geschäftsleitung an

Felix R. Ehrat, Group General Counsel, tritt per 1. Juni 2018 zurück Shannon Thyme Klinger zum Group General Counsel ernannt Robert Weltevreden zum Leiter Novartis Business Services ernannt ...
May 15, 2018 16:00 ET | Source: Novartis Pharma AG

Novartis successfully completes acquisition of AveXis, Inc.

The digital press release with multimedia content can be accessed here: Basel, May 15, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that it has completed the acquisition of AveXis,...
May 15, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*)

ARROW study to assess the mechanistic superiority of direct IL-17A inhibition (Cosentyx) over IL-23 inhibition (Tremfya®*) in clearing of Stelara®*-resistant psoriatic plaques[1] This is the...
May 15, 2018 00:45 ET | Source: Novartis Pharma AG

Novartis completes tender offer for all outstanding shares of AveXis, Inc.

Basel, May 15, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Novartis AM...
May 11, 2018 18:23 ET | Source: Novartis Pharma AG

Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis

New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)[1] In a landmark...
May 07, 2018 01:15 ET | Source: Novartis Pharma AG

Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globally

Alcon Cares to donate 100 reprocessed Infiniti® units to clinics helping underserved patients in Asia, Central and South America, and Africa over the next three years Program to increase...
May 02, 2018 16:05 ET | Source: Novartis Pharma AG

Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab

Holzkirchen, May 2, 2018 - Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing...
May 01, 2018 16:26 ET | Source: Novartis Pharma AG

Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma

Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response[1] Kymriah is the only...
May 01, 2018 01:00 ET | Source: Novartis Pharma AG

Novartis provides update on proposed acquisition of AveXis

Basel, May 1, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") applicable...